142 related articles for article (PubMed ID: 23750511)
1. Iatrogenic Creutzfeldt-Jakob disease from commercial cadaveric human growth hormone.
Appleby BS; Lu M; Bizzi A; Phillips MD; Berri SM; Harbison MD; Schonberger LB
Emerg Infect Dis; 2013 Apr; 19(4):682-4. PubMed ID: 23750511
[No Abstract] [Full Text] [Related]
2. Neuropathology of iatrogenic Creutzfeldt-Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of Abeta pathology.
Duyckaerts C; Sazdovitch V; Ando K; Seilhean D; Privat N; Yilmaz Z; Peckeu L; Amar E; Comoy E; Maceski A; Lehmann S; Brion JP; Brandel JP; Haïk S
Acta Neuropathol; 2018 Feb; 135(2):201-212. PubMed ID: 29209767
[TBL] [Abstract][Full Text] [Related]
3. Iatrogenic Creutzfeldt-Jakob disease presenting 24 years after human growth hormone administration.
Hirst C
Br J Hosp Med (Lond); 2005 Oct; 66(10):592-3. PubMed ID: 16255271
[No Abstract] [Full Text] [Related]
4. Creutzfeldt-Jakob disease 38 years after diagnostic use of human growth hormone.
Croes EA; Roks G; Jansen GH; Nijssen PC; van Duijn CM
J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):792-3. PubMed ID: 12023427
[TBL] [Abstract][Full Text] [Related]
5. Human growth hormone-related iatrogenic Creutzfeldt-Jakob disease--being aware of diagnostic features 25 years later.
Dixit K; Kreitschmann-Andermahr I; Basu A; Dick JP; Manoharan P; Shalet S; Brabant G
J Clin Endocrinol Metab; 2009 Aug; 94(8):2684-5. PubMed ID: 19657045
[No Abstract] [Full Text] [Related]
6. [Creutzfeldt-Jakob disease in 4 children treated with growth hormone].
Billette de Villemeur T; Gourmelen M; Beauvais P; Rodriguez D; Vaudour G; Deslys JP; Dormont D; Richard P; Richardet JM
Rev Neurol (Paris); 1992; 148(5):328-34. PubMed ID: 1448646
[TBL] [Abstract][Full Text] [Related]
7. Human growth hormone-related iatrogenic Creutzfeldt-Jakob disease with abnormal imaging.
Lewis AM; Yu M; DeArmond SJ; Dillon WP; Miller BL; Geschwind MD
Arch Neurol; 2006 Feb; 63(2):288-90. PubMed ID: 16476821
[TBL] [Abstract][Full Text] [Related]
8. [A patient with Creutzfeldt-Jakob disease following treatment with human growth hormone].
Roos RA; Wintzen AR; Will RG; Ironside JW; van Duinen SG
Ned Tijdschr Geneeskd; 1996 Jun; 140(22):1190-3. PubMed ID: 8692356
[TBL] [Abstract][Full Text] [Related]
9. Transmission of amyloid-β protein pathology from cadaveric pituitary growth hormone.
Purro SA; Farrow MA; Linehan J; Nazari T; Thomas DX; Chen Z; Mengel D; Saito T; Saido T; Rudge P; Brandner S; Walsh DM; Collinge J
Nature; 2018 Dec; 564(7736):415-419. PubMed ID: 30546139
[TBL] [Abstract][Full Text] [Related]
10. Correlation between Bioassay and Protein Misfolding Cyclic Amplification for Variant Creutzfeldt-Jakob Disease Decontamination Studies.
Bélondrade M; Jas-Duval C; Nicot S; Bruyère-Ostells L; Mayran C; Herzog L; Reine F; Torres JM; Fournier-Wirth C; Béringue V; Lehmann S; Bougard D
mSphere; 2020 Jan; 5(1):. PubMed ID: 31996421
[TBL] [Abstract][Full Text] [Related]
11. Factors Influencing the Incubation of an Infectious Form of Creutzfeldt-Jakob Disease.
Peckeu L; Brandel JP; Welaratne A; Amar E; Costagliola D; Haïk S
Clin Infect Dis; 2020 Mar; 70(7):1487-1490. PubMed ID: 31351441
[TBL] [Abstract][Full Text] [Related]
12. Ultrastructural pathology of Creutzfeldt-Jakob disease and fatal familial insomnia.
Liberski PP; Giraud P; Kopp N
Folia Neuropathol; 2000; 38(4):171-3. PubMed ID: 11693721
[TBL] [Abstract][Full Text] [Related]
13. Iatrogenic Creutzfeldt-Jakob disease following human growth hormone therapy: case report.
Caboclo LO; Huang N; Lepski GA; Livramento JA; Buchpiguel CA; Porto CS; Nitrini R
Arq Neuropsiquiatr; 2002 Jun; 60(2-B):458-61. PubMed ID: 12131950
[TBL] [Abstract][Full Text] [Related]
14. The French surveillance network of Creutzfeldt-Jakob disease. Epidemiological data in France and worldwide.
Brandel JP; Peckeu L; Haïk S
Transfus Clin Biol; 2013 Sep; 20(4):395-7. PubMed ID: 23587616
[TBL] [Abstract][Full Text] [Related]
15. [Creutzfeldt-Jakob disease after treatment with growth hormone: the point in July, 1998].
Brandel JP; Agid Y
Rev Neurol (Paris); 1998 Oct; 154(10):654-5. PubMed ID: 9846335
[No Abstract] [Full Text] [Related]
16. [Iatrogenic Creutzfeldt-Jakob disease. Lessons from cases secondary to extracted growth hormone in France].
Billette de Villemeur T; Pradel A
Transfus Clin Biol; 1994; 1(5):333-7. PubMed ID: 7812459
[TBL] [Abstract][Full Text] [Related]
17. Creutzfeldt-Jakob disease with unusually extensive neuropathology in a child treated with native human growth hormone.
Mikol J; Deslys JP; Zou WQ; Xiao W; Brown P; Budka H; Goutieres F
Clin Neuropathol; 2012; 31(3):127-34. PubMed ID: 22551916
[TBL] [Abstract][Full Text] [Related]
18. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues.
Bruce ME; McConnell I; Will RG; Ironside JW
Lancet; 2001 Jul; 358(9277):208-9. PubMed ID: 11476840
[TBL] [Abstract][Full Text] [Related]
19. Iatrogenic Creutzfeldt-Jakob disease 22 years after human growth hormone therapy: clinical and radiological features.
Furtner M; Gelpi E; Kiechl S; Knoflach M; Zangerl A; Gotwald T; Willeit J; Maier H; Ströbel T; Unterberger U; Budka H
J Neurol Neurosurg Psychiatry; 2008 Feb; 79(2):229-31. PubMed ID: 18202218
[No Abstract] [Full Text] [Related]
20. [Iatrogenic Creutzfeld-Jakob disease. Significance of cases observed after extracted growth hormone treatment].
Billette de Villemeur T
Rev Neurol (Paris); 1998 Oct; 154(10):651-2. PubMed ID: 9846334
[No Abstract] [Full Text] [Related]
[Next] [New Search]
